Search results
Results from the WOW.Com Content Network
The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. [2] In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7] In terms of the global market, India currently holds an accountable share and is known as the pharmacy of the world. [9] The country is the largest global supplier of generic medicine. [10] India produces more than 50% the world's vaccines. [11]
Indian pharmaceutical company Strides Pharma Science Ltd <SRID.NS> on Thursday received regulatory approval to start clinical trials of antiviral drug favipiravir, which has been touted as a ...
On 7 April 2014, India-based Sun Pharmaceutical and Japan-based Daiichi Sankyo jointly announced the sale of the entire 63.4% share of Ranbaxy from Daiichi Sankyo to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. [3]
It was sold to Strides Arcolab through a share purchase agreement with Haw Par Healthcare Limited, Singapore in September 2006 for approximately SGD$19.7 million. It is currently a part of Strides Arcolab which is listed on both the Indian stock exchanges Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify